Synergistic Bleeding Control Systems
Legal Citation
Summary of the Inventive Concept
The present inventive concept integrates the patented trigeminal and vagal nerve stimulation technology with distinct technologies like AI, IoT, blockchain, and advanced materials to create a more powerful system for reducing bleeding in various medical applications.
Background and Problem Solved
The original patent disclosed a system for accelerating clot formation at an injury site using non-invasive electrical stimulation of the trigeminal and vagal nerves. However, this technology has limitations in terms of real-time patient data monitoring, secure data storage, and personalized treatment protocols. The present inventive concept addresses these limitations by incorporating AI, IoT, blockchain, and advanced materials to create a more comprehensive and effective bleeding control system.
Detailed Description of the Inventive Concept
The synergistic bleeding control system comprises a neural stimulation apparatus that simultaneously stimulates the trigeminal and vagal nerves, an AI-powered controller that adjusts stimulation parameters based on real-time patient data from a wearable IoT sensor, and a blockchain-secured platform for secure storage and sharing of patient medical records. The system may also incorporate advanced materials like graphene-based electrode arrays for transcutaneous neural stimulation. The AI-driven predictive analytics enables personalized treatment protocols and real-time monitoring of bleeding risk.
Novelty and Inventive Step
The new claims introduce the innovative integration of AI, IoT, blockchain, and advanced materials with the patented trigeminal and vagal nerve stimulation technology, providing a synergistic effect that enhances the overall bleeding control system. The inventive step lies in the unexpected combination of these distinct technologies to create a more powerful and effective system for reducing bleeding in various medical applications.
Alternative Embodiments and Variations
Alternative embodiments of the synergistic bleeding control system may include variations in the type of AI algorithms used, the design of the wearable IoT sensor, or the specific advanced materials employed. Additionally, the system could be adapted for use in different medical applications, such as surgical procedures or emergency response situations.
Potential Commercial Applications and Market
The synergistic bleeding control system has significant commercial potential in the medical device industry, particularly in the areas of emergency medicine, surgery, and bleeding disorder treatment. The system's ability to provide personalized treatment protocols and real-time monitoring of bleeding risk could revolutionize the way bleeding is managed in various medical settings, offering a significant market opportunity.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biomedical engineering, specifically neural stimulation technologies for physiological intervention, with expertise in neurostimulation devices, signal processing, and medical electronics
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or medical device designer with advanced degree, knowledge of neural stimulation techniques, familiarity with control systems, signal processing, and medical device integration technologies
Obviousness Rationale
A PHOSITA would recognize that integrating AI, IoT, and advanced materials with the existing neural stimulation approach represents a predictable technological evolution. The core neural stimulation mechanism remains fundamentally consistent with the source patent, while the additional technologies provide incremental improvements in monitoring, personalization, and data management. These technological extensions represent standard engineering approaches to enhancing medical device functionality through computational and sensing technologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,788 |
|---|---|
| Title | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| Assignee(s) | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH |